Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen

摘要: Busulfan 16 mg/kg and cyclophosphamide 120 were used as conditioning prior to allogeneic marrow transplantation in 50 adult patients with acute nonlymphocytic leukemia (ANLL), lymphocytic (ALL), chronic myelogenous (CML). A standard risk group of 20 included those remission CML phase. high-risk 30 individuals refractory leukemia, relapse, following preleukemia, accelerated blastic Complete sustained complete engraftment achieved all evaluable patients. The duration aplasia was remarkably short (median 8 days), resulting a low infection rate during the period neutropenia, reduced need for blood product support, length hospital stay. Three-year actuarial relapse-free survival both standard-risk (88.9% +/- 10.5%) (50.5% 9.6%) groups compares favorably that reported total body irradiation (TBI) containing regimens.